Debattama R Sen
Overview
Explore the profile of Debattama R Sen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
3191
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Menzel L, Zschummel M, OMelia M, Zhou H, Lei P, Liu L, et al.
bioRxiv
. 2025 Feb;
PMID: 39990447
A diverse naive CD8 T cell repertoire is essential to provide broad protection against infection and cancer. Aging diminishes naive T cells, reducing potential diversity and leading to lymph node...
2.
Weiss S, Huang A, Fung M, Martinez D, Chen A, LaSalle T, et al.
Nat Immunol
. 2024 Sep;
25(10):1871-1883.
PMID: 39289557
PD-1 is a key negative regulator of CD8 T cell activation and is highly expressed by exhausted T cells in cancer and chronic viral infection. Although PD-1 blockade can improve...
3.
Chen A, Sen D
Cancer Res
. 2024 Jul;
84(19):3130-3131.
PMID: 39074365
Aging is one of the biggest risk factors for cancer development. More than 85% of all cancers occur in individuals above 55 years old, often accompanied by age-associated immune defects....
4.
Chen A, Jaiswal S, Martinez D, Yerinde C, Ji K, Miranda V, et al.
Nat Immunol
. 2024 May;
25(6):1033-1045.
PMID: 38745085
The etiology and effect of age-related immune dysfunction in cancer is not completely understood. Here we show that limited priming of CD8 T cells in the aged tumor microenvironment (TME)...
5.
Revach O, Cicerchia A, Shorer O, Petrova B, Anderson S, Park J, et al.
bioRxiv
. 2024 Feb;
PMID: 38405985
A central problem in cancer immunotherapy with immune checkpoint blockade (ICB) is the development of resistance, which affects 50% of patients with metastatic melanoma. T cell exhaustion, resulting from chronic...
6.
Podesta M, Cavazzoni C, Hanson B, Bechu E, Ralli G, Clement R, et al.
Nat Commun
. 2023 Nov;
14(1):7712.
PMID: 38001088
Follicular helper T (Tfh) cells are essential for the formation of high affinity antibodies after vaccination or infection. Although the signals responsible for initiating Tfh differentiation from naïve T cells...
7.
Baumgartner C, Ebrahimi-Nik H, Iracheta-Vellve A, Hamel K, Olander K, Davis T, et al.
Nature
. 2023 Oct;
622(7984):850-862.
PMID: 37794185
Immune checkpoint blockade is effective for some patients with cancer, but most are refractory to current immunotherapies and new approaches are needed to overcome resistance. The protein tyrosine phosphatases PTPN2...
8.
Fox D, Ebright R, Hong X, Russell H, Guo H, LaSalle T, et al.
NPJ Precis Oncol
. 2023 Mar;
7(1):25.
PMID: 36864091
Immune checkpoint blockade (ICB) has demonstrated efficacy in patients with melanoma, but many exhibit poor responses. Using single cell RNA sequencing of melanoma patient-derived circulating tumor cells (CTCs) and functional...
9.
Sun Y, Revach O, Anderson S, Kessler E, Wolfe C, Jenney A, et al.
Nature
. 2023 Jan;
615(7950):158-167.
PMID: 36634707
Despite the success of PD-1 blockade in melanoma and other cancers, effective treatment strategies to overcome resistance to cancer immunotherapy are lacking. Here we identify the innate immune kinase TANK-binding...
10.
Alspach E, Chow R, Demehri S, Guerriero J, Gujar S, Hartmann F, et al.
Cancer Immunol Res
. 2021 Sep;
9(11):1245-1251.
PMID: 34544686
Recent success in the use of immunotherapy for a broad range of cancers has propelled the field of cancer immunology to the forefront of cancer research. As more and more...